Bristol Myers Squibb, bluebird land once-high-stakes approval on BCMA CAR-T — and it bodes well for rival J&J
Almost a year after getting slammed by a surprise refuse-to-file letter, Bristol Myers Squibb and bluebird have been cleared to market the first BCMA CAR-T therapy.
Once a closely-watched event, the approval of ide-cel in multiple myeloma received a relatively muted welcome when it was announced Friday afternoon. It was largely expected by analysts, who were however surprised by parts of the label.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 112,800+ biopharma pros reading Endpoints daily — and it's free.